Study of XL820 Given Orally Daily to Subjects With Solid Tumors

NCT00350831 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Exelixis